BioSpace News Archive

An FDA advisory committee voted Wednesday that Ipsen’s fibrodysplasia ossificans progressive candidate palovarotene was effective and the benefits of the drug outweighed its risks.

The biopharma’s monoclonal antibody is the first to win approval for the two most common forms of generalized myasthenia gravis, a rare autoimmune and neuromuscular disorder.

Here are 10 career paths to consider that don’t include bench work, along with role descriptions and links to jobs available now on BioSpace’s job board.

Recent changes in the board of directors at Biogen has garnered attention due to potential conflicts of interest. Such conflicts vary widely, but one thing is clear: perception matters.

Patients treated in a Phase II study with Lilly’s retatrutide saw up to 24% weight loss at 48 weeks, driven by a triagonist mode of action that can bind and activate the GLP-1, GIP and glucagon receptors.

Though the topline data were sparse, Sanofi’s potentially first-in-class candidate amlitelimab improved Eczema Area and Severity Index scores in patients with moderate-to-severe atopic dermatitis.

Phase II results of MoonLake’s sonelokimab suggest superiority to the competition. Funds raised in the stock offering will support Phase III trials with an anticipated launch in 2027.

Blue Earth Diagnostics today announced inter- and intra-reader reproducibility results from its Phase 3 LIGHTHOUSE trial of POSLUMA® (flotufolastat F 18) injection (formerly referred to as 18F-rhPSMA-7.3) in newly diagnosed prostate cancer.

DeBogy Molecular Inc, a biotech startup that specializes in antimicrobial surface modification, announced that the study results of their antibacterial compound on medical implants have been published in the prestigious Journal of Orthopedic Research.

Artelo Biosciences, Inc. announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.